PNKD抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: HEPG2 and 231 cell lysates, Primary antibody: P02681(PNKD Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P02681(PNKD Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The PNKD (Paroxysmal Nonkinesigenic Dyskinesia) antibody is a tool used to detect the PNKD protein, encoded by the *PNKD* gene (also known as *MR-1* or *MYOFERLIN*). This gene is linked to a rare neurological disorder called paroxysmal nonkinesigenic dyskinesia (PNKD), characterized by episodic involuntary movements. The PNKD protein is highly expressed in the brain, particularly in neurons, and is implicated in regulating neurotransmitter release and synaptic function. Mutations in the *PNKD* gene, such as the common Ala7Val/Thr substitution, disrupt protein function, though the exact pathological mechanisms remain unclear.

PNKD antibodies are primarily used in research to study protein localization, expression levels, and interactions in neural tissues. They aid in elucidating PNKD's role in cellular processes, including its interaction with synaptic proteins or ion channels. Commercial PNKD antibodies are typically developed against specific epitopes, such as the N-terminal region, and validated via Western blot, immunohistochemistry, or immunofluorescence.

Research involving PNKD antibodies contributes to understanding dyskinesia pathophysiology and potential therapeutic targets. Challenges include ensuring antibody specificity due to protein homology with other ferlin family members. Ongoing studies aim to clarify PNKD's molecular functions and its broader implications in neuropsychiatric disorders beyond PNKD syndromes.